WO2022243907 - FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE
National phase entry:
Publication Number
WO/2022/243907
Publication Date
24.11.2022
International Application No.
PCT/IB2022/054640
International Filing Date
18.05.2022
Title **
[English]
FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE
[French]
FORMULATIONS DE 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHÉNOXY)-3-(TRIFLUOROMÉTHYL)PHÉNYL)-1,2,4-OXADIAZOL-5-YL)MÉTHYL)-5,5-DIMÉTHYL-1-(2-MORPHOLINOÉTHYL)IMIDAZOLIDINE-2,4-DIONE
Applicants **
NOVARTIS AG
Inventors
RIDRUEJO, Nuria Jimenez
LAKSHMAN, Jay Parthiban
RAYABANDLA, Sunil Kumar Mandala
TOWLER, Christopher Stephen
FAN, Yi
HARDY, Declan
HUANG, Zhihong
LOREN, Jon Christopher
MOLTENI, Valentina
SHAW, Duncan
SMITH, Jeffrey
Priority Data
63/191,293
20.05.2021
US
63/269,675
21.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
* |
| Recordal of a Change of the Applicant's Name/Address | * |
| Type of Assignment | * |
| Applicant's Legal Status | * |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under | * |
| Patent Delivery | * |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2841 | |
| EPO | Filing, Examination, Granting | 15031 | |
| Japan | Filing, Examination, Granting | 2569 | |
| South Korea | Filing, Examination, Granting | 3013 | |
| USA | Filing, Examination, Granting | 8740 |
Total:
32,194
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione and pharmaceutically acceptable salts thereof, processes for their production, and uses thereof, including in the treatment of ocular diseases and disorders such as dry eye disease and Meibomian gland dysfunction (MGD).[French]
Formulations de 3-((3-(4-(2-(isobutylsulfonyl)phénoxy)-3-(trifluorométhyl)phényl)-1,2,4-oxadiazol-5-yl)méthyl)-5,5-diméthyl-1-(2-morpholinoéthyl)imidazolidine-2,4-dione et de sels de qualité pharmaceutique de celle-ci, procédés pour leur production, et leurs utilisations, y compris dans le traitement de maladies et de troubles oculaires tels que le syndrome de l'œil sec 5 et un dysfonctionnement des glandes de Meibomius.